Department of Otolaryngology - Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eur Arch Otorhinolaryngol. 2024 Oct;281(10):5261-5266. doi: 10.1007/s00405-024-08728-4. Epub 2024 May 14.
The aim of this study is to evaluate the efficacy of heated humidified high flow nasal cannula (HFNC) therapy as a conservative treatment option for newborns suffering from nasal stenosis, a condition that often leads to respiratory distress and feeding difficulties. Given the increasing utilization of HFNC in various upper and lower respiratory tract indications, characterized by its flow-based mechanism and minimal mucosal damage, we seek to investigate its potential benefits in this specific patient population.
A retrospective chart review of newborns with congenital nasal stenosis treated with HFNC for respiratory distress or feeding difficulties in a pediatric tertiary center between 2014 and 2022. Data were collected for demographic characteristics, clinical presentation and ventilatory requirements, pre and post HFNC application.
Six infants with nasal stenosis were included in the study cohort. Five were diagnosed with congenital pyriform aperture stenosis, three of whom had additional midnasal stenosis. One patient had nasal synechiae. Two patients had failed surgical treatment and all patients failed conservative treatment prior to HFNC treatment. Following HFNC use, improvement was noted in oxygen saturations, heart and respiratory rates, meal volumes and weight. None of the patients required any additional sinonasal surgical treatment. No complications were observed.
In this case series, we present the first documented use of HFNC treatment for nasal stenosis, showing favorable results. Further studies with a larger cohort, wider range of conditions and extended follow-up periods are needed to establish the risks and benefits of HFNC for neonatal nasal stenosis.
本研究旨在评估加热湿化高流量鼻导管(HFNC)治疗作为患有鼻狭窄的新生儿的保守治疗选择的疗效,这种情况常导致呼吸窘迫和喂养困难。鉴于 HFNC 在各种上呼吸道和下呼吸道适应证中的应用越来越多,其特点是基于流量的机制和最小的粘膜损伤,我们试图研究其在特定患者群体中的潜在益处。
对 2014 年至 2022 年期间在儿科三级中心因呼吸窘迫或喂养困难而接受 HFNC 治疗的先天性鼻狭窄的新生儿进行回顾性图表审查。收集人口统计学特征、临床表现和通气需求的数据,以及 HFNC 应用前后的数据。
研究队列包括 6 例鼻狭窄婴儿。5 例诊断为先天性梨状孔狭窄,其中 3 例有鼻中隔狭窄。1 例患者有鼻粘连。2 例患者手术治疗失败,所有患者在接受 HFNC 治疗前均未成功接受保守治疗。在使用 HFNC 后,氧饱和度、心率和呼吸率、餐量和体重均有所改善。没有患者需要任何额外的鼻旁窦手术治疗。没有观察到任何并发症。
在本病例系列中,我们首次记录了 HFNC 治疗鼻狭窄的应用,结果良好。需要进一步进行更大队列、更广泛的疾病范围和更长随访期的研究,以确定 HFNC 治疗新生儿鼻狭窄的风险和益处。